Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%

Moderna stock is surging ahead of a closely watched cancer data readout in Madrid, and the stakes could not be higher for a company with nearly $800 million in quarterly losses and no approved cancer product yet.